Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agilent Technologies and BGI have collaborated to develop methodologies designated for next-generation genome-wide association studies.
Subscribe to our email newsletter
The new methodologies will assist scientists in pursuing disease and drug research, the companies said.
The collaboration aims to develop a next-generation super exome, which incorporates sequence regions believed to be more informative for specific human populations, using Agilent’s SureSelect technology.
As per the agreement, BGI has selected to use Agilent’s portfolio of solutions, including SureSelect target-enrichment system and 2100 bioanalyzers, for genomics research and next-generation sequencing tools.
BGI science and technology department associate director Hui Jiang said the company aims to develop research collaborations and provide support to scientists all over the world.
"Together with Agilent’s expertise, we can create more precise and accurate technology that can be deployed in large-scale research to better understand complex diseases, which may have differences between ethnicities," Jiang added.